What Is the Average Wait Time for a Heart Transplant?

The average wait time for a heart transplant in the United States has changed substantially over the past two decades, and the answer depends heavily on how sick you are when you’re listed. Under the current allocation system, the mean time on the waitlist is roughly two months for most candidates, down from over four months under the old system. But that average masks enormous variation: some people receive a heart within days, while others wait well over a year. Your medical urgency, blood type, body size, immune sensitivity, geographic location, and even your race all play a role in determining how long you personally might wait.

What the Numbers Actually Look Like

Before the United States overhauled its heart allocation policy in 2018, the median wait time for candidates listed in the highest-priority category was about a month, while those in the intermediate category waited closer to two or three months. But by 2012–2013, median wait times had climbed: half of all listed candidates waited roughly nine months for a transplant, up from about five months just eight years earlier.¹ The intermediate-priority group saw the most dramatic increase, with their median wait jumping from under three months to over eight months during that period. Those trends were a major reason the allocation system was redesigned.

After the 2018 policy change, the picture improved for many candidates. A study in JAMA Cardiology found that mean time on the waitlist dropped from about 135 days under the old system to roughly 55 days under the new one.² That reduction came alongside lower waitlist mortality: rates of death within 90 days of listing fell from about 6% to 5%, and one-year waitlist mortality dropped from around 13% to 12%. However, not every tier of candidates benefited equally, and the gains have not remained static over time.

How the Priority System Shapes Your Wait

The old allocation system sorted candidates into just three priority statuses. The 2018 overhaul expanded that to six tiers, aiming to better distinguish patients by how urgently they needed a heart and to reduce deaths on the waitlist.³ Under the old system, a patient on a mechanical heart pump and a patient in cardiogenic shock on temporary life support could end up in the same priority bucket. The new tiers try to separate those situations so the sickest patients get organs first.

The redesign shortened waits for the most critically ill, but it has created new bottlenecks. Patients listed in the new status 2 category, a relatively common listing tier, have seen their wait times creep upward. Each successive period after the policy change was associated with roughly a four-day increase in mean status 2 wait time, and that trend has continued.⁴ In other words, the system successfully shortened waits at the very top of the urgency ladder but may be slowly lengthening them one rung down.

Blood Type Is One of the Biggest Factors

If there is one variable that consistently predicts a longer wait, it is blood type. People with type O blood face the longest waits because they can only receive organs from type O donors, while type AB patients can accept hearts from any blood type. In pre-2018 data, type O candidates spent roughly five times longer on the waitlist than type AB candidates.¹ Under the new allocation system, wait times were still longest for blood type O and shortest for types AB and A.⁴ This disparity is an unavoidable consequence of how blood-type compatibility works and shows up in pediatric transplant data as well.

Beyond blood type, immune sensitization adds another layer of complexity. Your body may have developed antibodies against donor tissue from previous surgeries, blood transfusions, or pregnancies. This is measured by a metric called the calculated panel-reactive antibody level (CPRA). Candidates with very high sensitization, above 80%, were far less likely to receive a transplant and more than twice as likely to be removed from the list or die while waiting, compared to candidates with low sensitization.⁵ High sensitization essentially means fewer compatible donors exist for you, which narrows the pool and extends your wait.

Where You Live Matters

The United States is divided into organ procurement regions, and the ratio of people waiting to available donors varies widely across them. Registrations per million population have historically ranged from about 12 to 33 across the 11 regions, while transplants per million ranged from roughly 5 to 11.⁶ Regions with more candidates relative to donors naturally had longer median waits. The 2018 policy change broadened geographic sharing of donor hearts, with donors now traveling farther to reach recipients. Mean distance between donor and recipient hospitals jumped from about 157 miles to 279 miles after the change.² That has helped reduce regional disparities somewhat, though it introduces trade-offs in how long the heart is without blood flow during transport.

Wait Times for Children

Pediatric heart transplant waiting times follow a different pattern. After a 2016 allocation policy change specific to children, the highest-priority pediatric candidates over 25 kilograms (roughly school-age and older) experienced relatively short median waits: about 24 days for non-O blood types and 47 days for type O. But smaller children with type O blood waited much longer, with a median of 108 days.⁷ Smaller body size limits the pool of suitably sized donor hearts, compounding the blood-type disadvantage.

The benefits of allocation policy changes have also not been uniform across pediatric populations. Children with cardiomyopathy, the most common reason for pediatric listing, did not experience the same mortality benefits as children with congenital heart disease under the recent changes.⁸ Pediatric patients who are temporarily inactivated on the waitlist, often because of infections or other complications that make surgery too risky at that moment, also face substantially longer total wait times. Inactivated children had a median waitlist duration nearly three times longer than those who stayed continuously active.⁹

Ventricular Assist Devices and the Bridge-to-Transplant Trade-Off

Many candidates waiting for a heart transplant now receive a mechanical heart pump, called a left ventricular assist device (LVAD), to keep them alive until a donor heart becomes available. The share of waitlisted patients on these devices nearly tripled over a 15-year period, from about 13% in the early 2000s to roughly 29% by the mid-2010s.¹⁰ LVADs improve survival while you wait: patients on these devices had better outcomes during the listing period than patients managed with medications alone.¹¹

There is a catch, though. Because an LVAD stabilizes you, you may no longer qualify for the highest urgency tier, and your wait for an actual transplant can lengthen. Nationwide data show that while LVAD-supported patients had lower waitlist death rates, they also had a lower chance of actually receiving a transplant compared to medically managed patients.¹² In practical terms, the device keeps you alive longer but may push your transplant date further out. The new allocation system tried to address this by giving different urgency classifications depending on the type of device and how long it has been in place, but the tension between stabilization and priority remains a defining feature of the modern waitlist experience.

Expanding the Donor Pool to Shorten Waits

The fundamental problem driving long wait times is a shortage of donor hearts. Several innovations are beginning to chip away at that bottleneck. One of the most significant is the use of hearts from donors after circulatory death (DCD), where the heart stops before organs are recovered. Traditionally, only hearts from brain-dead donors were used. At one major program, incorporating DCD hearts cut median waitlist time from about 48 days to 19 days and nearly doubled the transplant rate, with no difference in one-year survival.¹³ A larger study found similar trends, with median waitlist time dropping from 2.8 months to 1.6 months as DCD transplants became routine, and the overall transplant rate rising from 65% to 73%.¹⁴ DCD hearts especially help candidates who have historically been hard to match, such as those with high immune sensitization or type O blood.

Another avenue is accepting hearts from donors infected with hepatitis C. With the advent of highly effective antiviral drugs that can cure hepatitis C in weeks, transplant programs began accepting these organs and treating recipients afterward. At one center, patients who consented to receive a hepatitis C-positive heart had a median wait of just four days from the time of consent, compared to a median of 28 days of waiting they had already accumulated before consenting.¹⁵ A separate program found that once it began accepting hepatitis C-positive donor hearts, its median waitlist time fell by almost half, from about 63 days to 34 days.¹⁶ Short-term outcomes for these recipients have been comparable to those receiving uninfected hearts.

Preservation technology is also evolving. Conventional transplant relies on packing a heart in cold storage, which limits how far it can travel before the organ deteriorates. Ex vivo perfusion systems keep the heart warm and beating outside the body, potentially allowing programs to accept hearts from more distant donors or from donors whose hearts would otherwise be considered marginal.¹⁷ Early experience in the United States suggests these devices can extend safe transport distances and broaden the usable donor pool.¹⁸

Racial and Ethnic Disparities on the Waitlist

Wait time numbers do not affect all populations equally. Black patients listed for heart transplant have been consistently less likely to receive one compared to White patients, even after adjusting for medical and demographic factors. Under the old allocation system, Black patients had roughly 13% lower odds of being transplanted. The 2018 policy change improved transplant rates for all groups, but Black patients still had about 10% lower odds of receiving a heart than White patients.¹⁹ When they did receive transplants, Black recipients faced higher post-transplant mortality as well.

Hispanic patients face a different but overlapping set of challenges. While their likelihood of being transplanted is similar to White patients’, Hispanic candidates had roughly 50% higher adjusted waitlist mortality in one large analysis.²⁰ Both Black and Hispanic patients were more likely to be listed at the highest urgency levels, suggesting they arrived on the waitlist sicker. The reasons behind these disparities are multifaceted: they include differences in referral patterns, access to transplant centers, insurance coverage, and the higher prevalence of type O blood in some minority populations, which as noted earlier carries the longest waits.

The Psychological Weight of Waiting

Waiting for a heart transplant is not just a medical experience. It takes a serious psychological toll. In one study, patients examined at the start of their waiting period and then re-evaluated just four months later showed significant increases in depression and physical symptoms, along with declining social activities and everyday functioning.²¹ A more recent assessment found that about a third of waitlisted patients had clinically meaningful mental distress, with anxiety affecting around 41% and depression affecting about 33%.²² Nearly all reported low perceived physical health.

Interestingly, not all research paints a uniformly bleak picture. An earlier study found that transplant candidates reported surprisingly low overall stress scores, with many relying on strategies like positive thinking and humor to cope.²³ The authors speculated that hope itself serves as a buffer and that patients may consciously downplay distress to avoid worrying family members. Still, the consensus in the transplant community is that psychosocial support should be a standard part of care during the waiting period, not an afterthought.

Does a Longer Wait Affect Your Outcome After Transplant?

This is a question many candidates and their families worry about, and the answer is nuanced. The best evidence suggests a modest but real effect: for every doubling of time spent on the waitlist, the odds of dying within one year after transplant increase by about 10%.¹ That relationship held across different urgency categories. The likely explanation is that prolonged waiting gives more time for complications such as kidney dysfunction, liver problems, or infections that weaken the body before surgery.

However, what happens to you while you wait may matter more than the raw duration. A model of waitlist mortality found that time-varying events during the waiting period, such as new neurological events, the need for dialysis, and respiratory complications, were far more predictive of outcomes than anything measured at the time of listing.²⁴ Neurological events, for instance, were associated with a more than thirteenfold increase in mortality risk. An older study found that waiting-list time by itself did not significantly affect post-transplant survival when other factors were controlled.²⁵ The takeaway is that a longer wait is a proxy for more things going wrong during that wait, rather than the passage of time being inherently harmful.

Xenotransplantation and the Possible Future Beyond the Waitlist

The most radical potential solution to the organ shortage is xenotransplantation: transplanting hearts from genetically modified animals, primarily pigs, into humans. The concept has moved from science fiction to early clinical reality, with a handful of compassionate-use cases generating global attention. Research is actively evaluating the approach’s promise and its remaining hurdles, including immune rejection, infection risk from animal viruses, and the durability of pig hearts in the human body.²⁶ If xenotransplantation eventually becomes routine, it could fundamentally change the equation by providing an essentially unlimited supply of donor organs. That reality is still years away from broad clinical use, but the pace of progress has accelerated considerably, and it remains the single most closely watched development in the transplant world.